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     The blood system serves as a key model for cell differentiation and cancer. It is orchestrated 
by precise spatiotemporal expression of the hematopoietic master regulator PU.11-4. PU.1 gene 
expression is regulated through enhancer-promoter interactions within a topologically 
associated domain (TAD)5,6. PU.1 levels increase during myeloid differentiation while failure 
to do so results in myeloid leukemia7. In contrast, T-cell differentiation requires PU.1 to be 
completely switched off8-10. Little is known about the precise mechanisms of PU.1 repression, 
physiological as in T-cell differentiation, or pathological as in leukemia. Here we demonstrate 
that the down-regulation of PU.1 mRNA is a dynamic process involving an alternative 
promoter11 in intron 3 that is induced by RUNX transcription factors driving noncoding 
antisense transcription. Core binding factor (CBF) fusions, RUNX1-ETO and CBFβ-MYH11 
in t(8;21) and inv(16) acute myeloid leukemia (AML)12, activate the PU.1 antisense promoter, 
thus shifting from sense towards antisense transcription and blocking myeloid differentiation. 
In patients with CBF-AML, we found that an elevated antisense/sense ratio represents a 
hallmark compared to normal karyotype AML or healthy CD34+ cells. Competitive interaction 
of the enhancer with the proximal or the antisense promoter are at the heart of differential PU.1 
expression during myeloid and T-cell development. Leukemic CBF fusions thus utilize a 
physiologic mechanism employed by T-cells to decrease sense PU.1 transcription. Our results 
identify the first example of a sense/antisense promoter competition as a crucial functional 
switch for gene expression perturbation by oncogenes. This novel basic disease mechanism 
reveals a previously unknown Achilles heel for future precise therapeutic targeting of 
oncogene-induced chromatin remodeling. 
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     To examine the developmental activation of the PU.1 (SPI1) locus (Fig.1a) throughout all 
human hematopoietic differentiation stages (Fig.1b), we analyzed publicly available data 
identifying open chromatin regions using the assay for transposase-accessible chromatin with 
high-throughput sequencing (ATAC-seq)13. We identified highly versatile cell type specific 
accessibilities at a conserved region in intron 3 that we previously identified as a promoter of a 
long noncoding antisense transcript (asRNA)11 (Fig.1c-d). Chromatin accessibility at the PrPr 
stayed constant compared to the antisense promoter (AsPr) during early myelopoiesis (Fig.1c) 
whereas in mature CD4+/CD8+ T-lymphoid cells these sites were absent (Fig.1d). For in-depth 
analysis of sense (mRNA) and antisense (asRNA) transcript levels, we performed compartment 
enriched Northern Blot and strand-specific reverse-transcription quantitative polymerase chain 
reaction (RT-qPCR) quantification assays (Extended Data Fig.1a-f) and RT-qPCR on sorted 
bone marrow progenitor and mature peripheral blood cells (Extended Data Fig.1g-h, 
Extended Table1). Quantification of chromatin accessibility and transcript expression revealed 
that during myelopoiesis, progenitors and differentiated cells constantly displayed higher PrPr 
accessibility and mRNA transcription compared to AsPr accessibility and asRNA expression 
(Fig.1e). In contrast, during lymphopoiesis, we found high AsPr accessibility and asRNA 
expression in lymphoid-primed multipotent progenitor (LMPP) and common lymphoid 
progenitor (CLP) populations which preceded locus shutdown in T cells (Fig.1f). Ratio 
calculations of AsPr/PrPr accessibility and asRNA/mRNA expression revealed a constant ratio 
for PU.1 promoters and transcripts during myelopoiesis (Fig.1g) but a striking AsPr and asRNA 
increase during lymphopoiesis reaching a peak before complete repression in T-cells (Fig.1h). 
Promoter accessibility ratios and transcript expression ratios demonstrated a strong correlation 
for each population (Fig.1i). Increased AsPr/PrPr accessibility ratios (Fig.1j) and increased 
asRNA/mRNA transcript ratios (Fig.1k) distinguished lymphoid from myeloid populations 
during blood cell differentiation. Thus, the ratio of antisense/sense transcription indicates 
cellular fate in hematopoiesis. To investigate the mechanisms that drive asRNA transcription, 
we investigated expression levels of hematopoietic transcription factors during thymic 
differentiation (Fig.1l). Using transcript sequencing (RNA-seq) of thymic progenitor cells14, 
we identified that increasing RUNX factor expression matched with decreasing PU.1 
expression in early thymic progenitor (ETP), CD1a- pro-T  and CD1a+ pro-T cells (Fig.1m-o, 
Extended Fig.1i-j). In addition, a consensus RUNX binding motif was located in PU.1 AsPr 
(Fig.1p) which specifically bound RUNX1 as well as RUNX3 in electromobility shift assays 
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(EMSA) using extracts from Jurkat and HL-60 cells (Fig.1q). We next designed a luciferase 
reporter assay in HEK293T cells transiently transfected with reporter plasmids containing PU.1 
AsPr and analyzed transactivation activity with increasing concentrations of each RUNX factor. 
RUNX1 and RUNX3 indeed showed dose-dependent AsPr transactivation (Fig.1r-s, Extended 
Fig.1k). RUNX factors (core binding factors) are frequently altered in human leukemia, most 
commonly as t(8;21)(q22;q22) or inv(16)(p13;q22) chromosomal translocations of so called 
core-binding factor (CBF) leukemias accounting for 15% of all AML cases12,15. We therefore 
tested the oncogenic fusion proteins RUNX1-ETO (t8;21) and CBFB-MYH11 (inv16) and 
found, similarly to wild type RUNX1 and RUNX3, that RUNX1-ETO and CBFβ-MYH11 
fusions dose-dependently induced transactivation of PU.1 AsPr (Fig. 1t-u). These experiments 
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Fig. 1 | PU.1 antisense promoter activated by RUNX factors during T-lymphoid differentiation. a, Schematic of PU.1 locus: Proximal 
promoter (PrPr, blue arrow box), antisense promoter (AsPr, red arrow box), coding mRNA (blue line), antisense RNA (asRNA, red line), -
17kb enhancer (upstream regulatory element, URE, grey box). b, Human hematopoietic cell differentiation hierarchy (HSC-MPP,  
hematopoietic stem cell and multipotent progenitor; CMP, common myeloid progenitor; MEP, megakaryocyte-erythroid progenitor; GMP, 
granulocyte-macrophage progenitor; LMPP, lymphoid-primed multipotent progenitor; CLP, common lymphoid progenitor; Erythr., 
erythrocyte; Plat., platelet, Mono., monocyte; Gran., granulocyte). c-d, Aligned reads from ATAC-seq of PU.1 locus during c. myelopoiesis 
and d. lymphopoiesis (RM Corces et al.). e-f, URE-adjusted peak quantification values for AsPr and PrPr by ATAC-seq (upper panel) and 
PU.1 mRNA and asRNA (respectively dark red and dark blue) transcript profile using RT-qPCR (lower panel) for each population (mean value 
± s.e.m.) in  e, myelopoiesis (Population, replicates for ATAC-seq/RT-qPCR; HSC-MPP, n=13/9; CMP, n=8/8; GMP, n=7/9; MEP, n=7/10; 
Monocyte, n=6/6) and f, lymphopoiesis (Population, replicates for ATAC-seq/RT-qPCR; LMPP, n=3/4; CLP, n=5/4, T cell CD4+, n=5/6; T 
cell CD8+, n=5/6). g-h, Ratio of AsPr to PrPr (light brown) and asRNA to mRNA (dark brown) for each population (mean value ± s.e.m.) in 
g. myelopoiesis and h. lymphopoiesis. i, Correlation analysis of promoter chromatin accessibility ratios to transcript expression ratios. 
Regression line with Pearson correlation coefficient. j-k, Promoter and transcript ratio analysis in bone marrow hematopoietic progenitors for 
j. AsPr/PrPr chromatin accessibility ratio and k. asRNA/mRNA transcript expression ratio (mean value ± s.e.m.). Mann-Whitney-U test; LMPP 
versus CMP; CLP versus combined GMP/CMP (*P < 0.05, ***P < 0.001). l, Schematic of the human thymic T-lymphoid differentiation 
hierarchy (CLP, common lymphoid progenitor; ETP, early thymic progenitor). m-o, Gene expression by transcript sequencing (RNA-seq, D 
Casero et al.) in thymic progenitors and differentiated T cells (pro-T, CD1a- pro-T  cell; CD1a, CD1a+ pro-T cell; DP, double-positive 
CD4+/CD8+ T cell; CD4, CD4+ T cell; CD8, CD8+ T cell) for m. PU.1, n. RUNX1 and o. RUNX3 hematopoietic transcription factors (mean 
value relative to GAPDH housekeeping gene ± s.e.m., n = 2 per population). p, Schematic representation of the PU.1 locus with the antisense 
promoter containing a consensus RUNX binding site (black square). q, Gel electromobility shift assay (EMSA) with labelled PU.1 AsPr probe 
oligonucleotide in the presence of RUNX1 (in Jurkat cell line) or RUNX3 antibody (in HL-60 cell line) (RUNX compet. Probe, competition 
probe with mutated RUNX binding site). r-u, Luciferase reporter assays in HEK293T cells transiently transfected with PU.1 AsPr reporter 
plasmid and increasing r. RUNX1, s. RUNX3, t. RUNX1-ETO and u. CBFβ-MYH11 expression plasmids (plasmid concentration (ng) mean 
± s.e.m., n = 4). Student T-test; 0 ng control group versus individual expression plasmid groups (*P < 0.05; **P < 0.01; ***P < 0.001). We 
acknowledge somersault1834 (www.somersault1824.com) for providing the hematopoietic cell illustrations. 
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     To investigate if in CBF leukemia the ratio of antisense/sense transcription is altered, we 
analyzed PU.1 mRNA and asRNA expression in a cohort of patient samples of normal 
karyotype AML (NK-AML), CBF-AML, and CD34-enriched healthy bone marrow samples. 
Strikingly, we found elevated PU.1 asRNA and decreased PU.1 mRNA expression resulting in 
a highly significant increased asRNA/mRNA ratio in CBF-AML patients (Fig2a-c, Extended 
Fig.2a). Similarly, we examined open chromatin regions of PU.1 determined in patient samples 
by DNaseI-sequencing (DNase-seq)16. Compared to NK-AML we found increased AsPr DNase 
hypersensitivy sites (DHS) in t(8;21) and inv(16) CBF-AML subgroups and increase AsPr/PrPr 
promoter DHS ratios in t(8;21) alone (Fig2d-f, Extended Fig.2b).To probe its functional 
relevance in CBF-AML we depleted PU.1 asRNA using lentiviral small-hairpin RNA (shRNA) 
in the t(8;21) leukemic cell line, Kasumi-1 (Fig.2g, Extended Fig.2c-e). PU.1 asRNA reduction 
lead to increased PU.1 mRNA levels (Fig.2h), and loss of the CD34 surface marker 
characteristic for immature cells (Fig.2i). As expected for PU.1 increase2,3, the cell cycle was 
arrested (Fig.2j) and cells increasingly entered apoptosis (Fig.2k). Importantly, PU.1 asRNA 
depletion was associated with a loss of in vivo leukemogenicity in a (NOD/SCID) xenograft 
model (Fig.2g, l). Cytospins of isolated targeted Kasumi-1 cells exhibited a myeloid mature 
differentiation phenotype compared to controls (Fig.2m). Other pathophysiologic alterations 
such as splenomegaly and bone whiting related to massive leukemic infiltration were inhibited 
in asRNA depleted compared to controls (Fig.2n-o). These data demonstrate that PU.1 
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Fig. 2 | PU.1 antisense activation in core binding factor leukemia. a-c, Transcript quantification for a. PU.1 antisense (asRNA, red), b. 
mRNA (blue) and c. asRNA/mRNA ratio calculation in CBF-AML (n = 36), normal karyotype AML (NK-AML, n = 25) patient samples and 
normal CD34-enriched bone marrow (BM CD34+, n = 9) from three patient cohorts (mean value ± s.e.m.) (*P < 0.05; **P < 0.01; ns, non-
significant). d-f, Promoter quantification for d. PU.1 antisense promoter (AsPr, light red), e. proximal promoter (PrPr, light blue) and f. 
AsPr/PrPr ratio calculation in t(8;21)-AML (n = 3), inv(16)-AML (n = 2) and normal karyotype AML (NK-AML, n = 19) patient samples 
(mean value ± s.e.m.) (*P < 0.05) (SA Assi et al.). g, Experimental workflow of shRNA knockdown of PU.1 antisense RNA (shPU.1as) in 
Kasumi-1 followed by fluorescence-activated cell sorting (FACS) and xenografting into immunodeficient (NSCID) mice. h, PU.1 mRNA and 
asRNA expression in Kasumi-1 (mean value ± s.e.m., n = 4) (*P < 0.05, **P < 0.01).  i, CD34 surface marker and viability kinetics assessed 
by flow cytometry after shPU.1as in Kasumi-1 (mean CD34 percentage relative to day2, mean viability relative to day2 ± s.e.m., n = 4) (*P < 
0.05). j-k, Assays for j. cell cycle stages after shPU.1as and k. cell viability (Propodium Iodide, PI; Annexin V, AnnV; mean value ± s.e.m., n 
= 4) in Kasumi-1 cells (mean value ± s.e.m., shControl n = 5, shPU.1as n = 6) (*P < 0.05, **P < 0.01, ***P < 0.001). l, Survival probability 
of NOD-SCID mice xenografted with Kasumi-1 cells after shPU.1as versus shControl, (n = 7). m, May Grünwald/Giemsa cytospins for 
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     To further dissect the mechanism of how CBFs could drive PU.1 antisense transcription, we 
first depleted RUNX1-ETO using lentiviral small-hairpin RNA knockdown (shRUNX1-ETO) 
in t(8;21) Kasumi-1 cells (Fig.3a-b, Extended Fig.3a-b). Similar to PU.1 antisense depletion 
(Fig.2g-h), RUNX1-ETO depletion resulted in a loss of CD34 surface marker expression and 
a drop in cell viability (Fig.3c, Extended Fig.3c-d). Moreover, Giemsa staining of isolated 
targeted Kasumi-1 cells identified a mature myeloid differentiation phenotype compared to 
controls (Fig.3d). RNA-seq confirmed a switch towards myeloid differentiation after RUNX1-
ETO depletion (Fig.3e, Extended Fig.3e) accompanied by increase of PU.1 expression and a 
loss of CD34 expression (Fig.3f). We next investigated PU.1 AsPr and PrPr chromatin 
accessibility and corresponding transcript levels in Kasumi-1 (t8;21) and ME-1 (inv16) cells 
after RUNX1-ETO knockdown or after specific CBFβ-MYH1 inhibition using a small 
molecule inhibitor of oncoprotein multimerization (AI-10-49)17,18, respectively. After CBF 
targeting, we identified decreased AsPr and relatively increased PrPr accessibility resulting in 
a shift towards a myeloid differentiation prone decreased AsPr/PrPr ratio in both models 
(Fig.3g-h). Similarly, CBF depletion resulted in decreased PU.1 asRNA, and increased mRNA 
levels (Fig.3i), with a decreased asRNA/mRNA ratio associated with myeloid differentiation 
(Fig.3j, Fig.1g). To directly detect strand-specific effects of CBFs on transcription we used 
precision nuclear run-on sequencing (PRO-seq) mapping of active RNA polymerases. 
Importantly, quantified PRO-seq reads at AsPr and AsPr/PrPr ratios decreased after RUNX1-
ETO depletion in Kasumi-1 cells (Fig.3k). Noteworthy, aligned PRO-seq reads started at the 
previously identified RUNX binding site at the PU.1 AsPr (Fig.3l). These experiments 
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Fig. 3 | Oncogenic core binding factors shift PU.1 sense to antisense transcription. a, Scheme of shRUNX1-ETO knockdown design. b, 
RUNX1-ETO RT-qPCR after RUNX1-ETO knockdown at day2 and day9 in Kasumi-1 cells relative to GAPDH housekeeping gene (mean 
value ± s.e.m., n = 3). c, CD34 surface marker and viability kinetics assessed by flow cytometry after shRUNX1-ETO in Kasumi-1 cells (± 
s.e.m., n = 2). d, May Grünwald/Giemsa cytospins for morphology analysis of Kasumi-1 cells. e, Heatmap of gene expression by RNA-seq 
after shRUNX1-ETO in Kasumi-1 at day2 and day9 (biological triplicates, n = 5810 genes, cut-off FDR < 0.001,). Gene expression of 
shRUNX1-ETO Day9 compared to shControl Day2-Day9 and shRUNX1-ETO Day2. f, Gene expression of shRUNX1-ETO Day9 compared 
to shControl Day2-Day9. g-h, URE-adjusted peak quantification values by ATAC-seq for PU.1 antisense (AsPr, red) and proximal promoter 
(PrPr, blue) exhibited as AsPr/PrPr ratio (mean value ± s.e.m.) for g. RUNX1-ETO knockdown in Kasumi-1 cells (2 days after lentiviral 
transduction, n = 3) and for h. AI-10-49 inhibitor treatment of ME-1 cells (6 hours after treatment, n = 2). i, PU.1 asRNA and mRNA transcript 
expression after shRUNX1-ETO in Kasumi-1 cells (mean value ± s.e.m., n = 6, 2 days after lentiviral transduction) and AI-10-49 inhibitor 
treatment of ME-1 cells (mean value ± s.e.m., n = 3, 6 hour treatment). j, Ratio of PU.1 asRNA and mRNA transcript expression after 
shRUNX1-ETO in Kasumi-1 cells and AI-10-49 inhibitor treatment in ME-1 cells. k, Aligned reads of PRO-seq with quantified peaks for 
PU.1 AsPr, PrPr, and AsPr/PrPr ratio (right, mean value ± s.e.m.) after shRUNX1-ETO in Kasumi-1 cells (2 days after lentiviral transduction, 
n = 2). l, Aligned PRO-seq reads after RUNX1-ETO knockdown start at the RUNX binding site in PU.1 AsPr. 
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     The -17kb URE creates a regulatory loop with PU.1 PrPr for mRNA expression2. 
Interestingly, the LMPP population presented increased chromatin accessibility at the -17kb 
URE region (Extended Fig.4a-b). We hypothesized that a shift in loop formation towards URE 
and AsPr instead of PrPr might account for the shift from sense towards antisense transcription 
in T-cell progenitors (Fig.1e-f). To test this idea, we examined chromosomal conformation 
capture sequencing (Hi-C) data from early T-lymphoid (Jurkat)19 and myeloid (HL-60)20 cell 
lines and analyzed PU.1 locus loop formations. While T-lymphoid cells demonstrated an 
interaction of the URE with intron 3 at the AsPr region, myeloid cells displayed an open locus 
with an URE-PrPr interaction (Fig.4a). We therefore performed in-depth analyses of interacting 
PU.1 chromosomal structures in both cell lines using chromosomal conformation capture 
assays (3C) (Fig.4b). Quantification of URE to AsPr (URE-AsPr) and URE to PrPr (URE-PrPr) 
cross-linking frequencies as well as quantification of PU.1 sense and antisense transcripts 
demonstrated increased URE-AsPr cross-linking frequencies and increased PU.1 asRNA 
expression in T-lymphoid Jurkat cells (Fig.4c). In contrast, in myeloid HL-60 cells URE-PrPr 
cross-linking frequency and PU.1 mRNA expression were increased (Fig.4d). These data 
suggest a model of two competing promoters for either T-lymphoid or myeloid differentiation 
(Fig.4e). To investigate if RUNX1-ETO plays a direct role in regulating the interplay between 
the two promoters and the URE, we examined chromatin immunoprecipitation sequencing 
(ChIP-seq) data21. RUNX1-ETO strongly binds to both the AsPr and the URE, with binding 
decreasing after RUNX1-ETO knock-down (Fig.4f) confirming that RUNX1-ETO binds both 
regions directly through conserved RUNX sites22,23 (Fig.1p). We further hypothesized that the 
oncogenic fusion protein could promote a T-lymphoid like chromosomal conformation in 
which the URE interacts with the AsPr. We thus evaluated if RUNX1-ETO depletion could 
revert a myeloid state on chromosomal conformation capture sequencing using promoter 
capture hi-C (CHIC) for enriched annotated promoters24.  Indeed, a flip towards an increased 
URE-PrPr interaction was detected (Extended Fig.4c). This idea was confirmed by 3C 
chromosomal conformation analysis showing that after RUNX1-ETO depletion URE-AsPr 
cross-linking frequencies decreased while URE-PrPr increased (Fig.4g) with a concomitant 
decrease in PU.1 asRNA and an increased in PU.1 mRNA levels (Fig.4h). Our data demonstrate 
that t(8;21) cells adopt a T-lymphoid like interaction state thus switching from PU.1 mRNA 
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Fig. 4 | RUNX1-ETO induces a T-like chromosomal conformation. a, Chromosomal conformation capture sequencing (Hi-C) in Jurkat 
(upper half) and HL-60 (lower half) cell lines (B Lucic et al. and Y Li et al.). Black dots indicate the chromosomal looping. b, Schematic 
representation of chromosomal conformation capture assay (3C) for proximity quantification of indicated elements. c-d, PU.1 locus 
chromosomal conformation capture (3C) and transcript expression c. in Jurkat and d. in HL-60 cells (mean value ± s.e.m., 3C n = 8, RT-qPCR, 
n = 3). e, Model of competing sense/antisense promoters. f, Aligned reads of RUNX1-ETO ChIP-seq after small interfering RNA knockdown 
of RUNX1-ETO (siRUNX-ETO) and mismatch control (siControl) (A Ptasinska et al.). g, 3C in Kasumi-1 after siRUNX1-ETO (siRE) and 
siControl (siCtrl) (mean value ± s.e.m., *p<0.05, n = 3). Mann-Whitney-U test; siRE group versus siCtrl group (**P < 0.01, ***P < 0.001, n 
= 8). h, Transcript quantification in Kasumi-1 after siRUNX1-ETO and siControl (mean value ± s.e.m., *p<0.05, n = 8) of RUNX1-ETO 
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     Our findings revealed a key mechanism of CBF leukemias which account for 15% and thus 
the largest group of human acute leukemias12,15. We previously reported that the subversion of 
terminal myeloid differentiation in CBF leukemias is correlated with low levels of PU.1 
expression23. Conversely, the introduction of PU.1 into CBF RUNX1-ETO leukemic cells 
induced cellular differentiation and stopped leukemic outgrowth, although the underlying 
mechanisms have remained unclear25,26. We here provide evidence that CBFs regulate the 
balance between PU.1 sense and antisense transcription that affects PU.1 levels and thus 
myeloiesis7. In addition to PU.1 antisense transcription interfering with PU.1 translation11, our 
data demonstrate reduced mRNA transcription by re-directing a key enhancer away from the 
proximal promoter towards a promoter of a long non-coding antisense transcript. Recent global 
analyses of 2,658 whole cancer genomes revealed the presence of non-coding driver mutations 
27 whose functional role could be crucial, since 60% of the genome are transcribed28,29. The 
promoter of long non-coding transcript PVT1 was recently reported to directly compete with 
oncogenic MYC promoter for binding a shared set of enhancers, and mutations in the PVT1 
promoter were found in breast cancer and malignant lymphoma30. The mechanisms how and if 
these mutations shift the competition towards the oncogenic MYC promoter have remained 
unclear. In cancer, oncogenes can be activated through genetic translocations that directly juxta-
position the enhancer to an oncogene such as GFI1 or GFIB in childhood medulloblastoma31 
or EVI1 in rare cases of leukemia32. Our findings extend this promoter competition model to a 
non-coding promoter and provide an explanation how enhancer-promoter interactions are 
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MATERIAL AND METHODS 
 
Normal donor samples, AML patient samples and cell lines 
Normal donor human bone marrow aspirations, peripheral blood cells and AML patient samples 
for RT-qPCR assays were obtained from the Division of Hematology at Medical University of 
Graz, Austria, and the Division of Hematology and Hemostaseology at Medical University of 
Vienna, Austria. Each sample was freshly sorted after Ficoll-Paque mononuclear cell separation 
revealing >80% blast cells. Material from patients and healthy donors was obtained with 
approval from the ethics committees at Medical University of Graz (vote number 26369 
ex13/14) and Medical University of Vienna (vote number 1184/2014).  
 
Kasumi-1 cells were grown in RPMI1640 supplemented with 20% fetal calf serum (FCS). HL-
60 and Jurkat cells were grown in RPMI1640 supplemented with 10% fetal calf serum (FCS). 
HEK293T and HEK-LentiX were grown in DMEM supplemented with 10% fetal calf serum 
(FCS). Kasumi-1, HL-60, Jurkat and HEK293T cell lines were obtained from the DSMZ cell 
line repository. HEK-LentiX cell line for lentivirus production was purchased from Takara Bio. 
ME-1 cells were purchased from DSMZ and cultured in RPMI1640 with 20% fetal bovine 
serum, 25 mM HEPES and 100 U/ml Penicillin/ Streptomycin. 
 
Flow cytometry 
Flow cytometry single-cell suspensions were analyzed by flow cytometry using the following 
monoclonal antibodies (mAbs) conjugated with fluorescein isothiocyanate (FITC), 
phycoerythrin (PE), PE-Cyanine7 (PE-Cy7), Peridinin-chlorophyll proteins cyanine5.5 
(PerCP-Cy5.5), allophycocyanin (APC), APC-Cy7 and Brilliant Violet 570™ (BV605) 
obtained from BD Pharmingen (BD) or BioLegend (San Diego, CA): CD3 (FITC, HIT3a), CD3 
(PE-Cy7, SK7), CD4 (PE, Leu3a), CD8 (APC-Cy7, RPA-T8), CD10 (PE-Cy7, HI10a), CD14 
(FITC, M5E2), CD19 (FITC, SJ25C1), CD19 (APC, HIB19), CD34 (PE, 8G12), CD38 (APC-
Cy7, HB-7), CD45RA (BV605, HI100), CD66b (FITC, G10F5), CD123 (APC, 6H6), CD235a 
(FITC, HI264). Viable cells were identified by 4',6-diamidino-2-phenylindole (DAPI) 
exclusion. Cells were analyzed by FACSAria Fortessa flow cytometer (BD Biosciences) or 
sorted by FACSAria Fusion (BD Biosciences) and MoFlo Astrios EQ (Beckman Coulter). 
FlowJo (Tree Star) was used for data analysis. 
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Reverse transcription quantitative PCR 
For reverse transcription quantitative PCR (RT-qPCR), total RNA was extracted using Trizol 
according to manufacturer’s protocol (Gibco). Quantification of PU.1 mRNA, PU.1 asRNA 
and GADPH expression in sorted normal bone marrow cells, normal peripheral blood 
mononuclear cells and AML patient samples was performed using Taqman RT-qPCR RNA-to-
Ct 1-Step Kit (Applied Biosystems). GAPDH housekeeping gene was quantified using pre-
developped TaqMan human GAPDH endogenous control (Applied Biosystems) according to 
manufacturers’ protocol. Quantification of RUNX1-ETO for assessing knockdown efficiency 
was performed using high-capacity RNA-to-cDNA Kit and SYBR qPCR Green PCR Master 
Mix (Applied Biosystems). Quantification of PU.1 mRNA, PU.1 asRNA and GADPH 
expression in cell lines was performed using strand-specific reverse transcript SuperScriptIII 
First-Strand Synthesis System (InVitrogen) and GoTaq Probe qPCR Master Mix (Promega) 
according to manufacturers’ protocol. GAPDH housekeeping used oligodT as primer for 
stranded cDNA generation. Primers used are described in Extended Table2. 
 
Electrophoretic mobility shift assays (EMSA)  
Nuclear extracts from Jurkat cells were prepared using a Nuclear Extract Kit (40010, Active 
Motif), according to manufacturer's recommendation. EMSA was performed using NUSHIFT 
kit (2005350; Active Motif), according to manufacturer's recommendation and as previously 
reported (Di Ruscio et al.). Supershift analysis was carried out by antibodies to RUNX 1 or 
RUNX 3 (Active Motif cat# 39300 and 39301, respectively). The gel was exposed to X ray film 
and/or phosphorimaging screens. Oligonucleotide sequences are described in Extended Table2. 
 
Luciferase reporter assay: 
HEK293T cells at 80% confluence in 24-well plate were transfected with pXP2 Firefly 
luciferase, pRL-CMV Renilla luciferase, CBFb, and increasing RUNX1, RUNX2, RUNX3, 
RUNX1-ETO or CBFb-MYH11 (+RUNX1) expression plasmids (0, 10, 50, 100 and 200 ng). 
Luciferase activity was measured 48h after transfection using the Dual-Glo Luciferase Reporter 
Assay System (Promega) and normalized to Renilla luciferase activity. 
 
Lentivirus production and gene knockdown 
Lentivirus was produced by transfection of HEK293T-LentiX (Takara Bio) using PEI 
(Polysciences) of shRNA-expressing viral vectors with the packaging plasmids pCMVR8.74 
and pMD2.G. Virus-containing supernatants were cleared of cellular debris by 0.45μm 
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filtration, concentrated and mixed with 8 μg/ml polybrene. Target cells were exposed for at 
least 48h to lentiviral supernatant at a multiplicity of infection (MOI) of 4 before downstream 
applications. Guide-strand sequences for Renilla (shControl), RUNX1-ETO (shRUNX1-ETO) 
and PU.1 asRNA (shPU.1as) lentiviral shRNA knockdown (sequences in Extended Table2) 
were cloned in an optimized ‘miRE’ context containing GFP33. For RUNX1-ETO knockdown 
by small-interfering RNA (siRNA), Kasumi-1 cells were transfected with RUNX1-ETO or 
mismatch control siRNA (sequences in Extended Table2). Cells were collected 24h after 
transfection for RUNX1/ETO knockdown efficiency assessment depletion and after an 
additional 40h for cross-linking or RNA isolation21. 
 
RNA isolation and Northern Analysis 
RNA isolation, electrophoresis, transfer and hybridization were carried out as described34. 
Polyadenylated mRNAs were selected according to the MicroPoly(A)PuristTM purification kit 
(Ambion). Preparation of separate nuclear and cytoplasmic fractions was performed according 
to the ParisTM kit (Ambion). Northern Quantitative analysis was performed on the Storm 
Phosphorimager.  The antisense-specific probe - mixture of two cloned PCR products are 
described in Extended Table2. 
 
RNA-seq 
Total RNA was prepared using Trizol (Ambion) and processed for sequencing using the 
NEBNext rRNA Depletion Kit and NEBNEXT Ultra II Direction RNA Library Prep Kit for 
Illumina. Raw RNA-seq reads were processed using Trim Galore! software 
(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) and aligned to GRCh38 
using STAR35. Differential gene expression between groups was calculated using the R package 
DESeq2 and a FDR < 0.001 was used as cut-off for differential gene expression. Heatmap data 
visualization was done using ClustVis36. Gene Ontology analyses were performed using 




Chromatin accessibility mapping was performed using the ATAC-seq technology. In brief, 105 
cells were washed once in 50μl PBS and resuspended in a transposase reaction mix containing 
12.5 μl 2 × TD buffer, 2 μl transposase (Illumina), 10.5 μl nuclease-free water and 0.01% NP-
40. Tagmentation was performed for 30 min at 37 °C. The optimum number of amplification 
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cycles was estimated by qPCR reaction as previously described38. Fragments larger than 
1,200 bp were excluded by SPRI size selection. DNA concentration was measured using a Qubit 
fluorometer (Life Technologies). Libraries were amplified using custom Nextera primers39 
followed by sequencing using the Illumina HiSeq3000/4000 platform. Raw .fastq files were 
adapter trimmed using Trim Galore! software 
(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) and aligned to GRCh37 
using bowtie240. Reads corresponding to mitochondrial DNA were removed using samtools 
(samtools view -@ 20 -h $i | grep -v MT | samtools sort)41. Picard tools 
(http://broadinstitute.github.io/picard) were used to mark duplicate reads arising during PCR as 
artefacts of the library preparation procedure followed by duplicate read and multimapper 
removal by samtools (samtools view -@ 20 -h -b -q 30 -F 1024). Bigwig files were generated 
using deepTools, peaks were called by MACS2 and quantified using the R package diffbind42. 
Intensity values were adjusted to the PU.1 -17kb URE; a quantification inferior to 1:8th of both 
AsPr and PrPr was used as a filter for outliers. Raw ATAC-seq data were deposited in the 
ArrayExpress database (Accession ID: E-MTAB-9021). 
 
PRO-seq library preparation 
Precision nuclear run-on sequencing (PRO-seq) for transcriptionally-engaged polymerases in 
Kasumi-1 after lentiviral small-hairpin RNA (shRNA) knockdown at a multiplicity of infection 
(MOI) of 4. Nuclei isolation was performed as described in Y. Zhao and colleagues (Cell Rep, 
2016). Briefly, 25 million Kasumi-1 cells were collected 48h after lentiviral transduction for 
RUNX1-ETO knockdown and resuspended in cold swelling buffer followed by Dounce 
homogenization. Cells were centrifuged and washed with lysis buffer. Nuclei were centrifuged 
and washed again with lysis buffer followed by freezing buffer and stored at -80°C. Nuclear 
run-on (NRO) assays were performed with 2 biotin-11-NTPs (biotin-11-CTP and biotin-11-
UTP, Jena Bioscience) as described in D. B. Mahat and colleagues (Nat Protoc, 2016). Briefly, 
nuclei were thawed on ice while the NRO mix was pre-equilibrated at 30°C. NRO was 
performed at 30°C, terminated with the addition of Trizol-LS (Ambion) and followed by RNA 
nuclear extraction. Nuclear RNA was fragmented by base hydrolysis and enriched for biotin-
labelled RNA with Streptavidin beads (Dynabeads M280 Streptavidin, InVitrogen). Nascent 
biotinylated RNA was ligated with 3’-VRA RNA adaptor (5’Phos-
GAUCGUCGGACUGUAGAACUCUGAAC-3’invdT). Ligated RNA was purified by a 
second round of Streptavidin beads enrichment and ligated with 5’-VRA RNA adaptor (5’-
CCUUGGCACCCGAGAAUUCCA-3’). Ligated RNA was purified by a third round of 
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Streptavidin beads enrichment followed by a reverse transcription step using SuperScript III 
First-strand synthesis (Invitrogen). Size and quantity of cDNA library preparation is assessed 
by PCR and determined the number of cycles for library amplification. After full-scale PCR 
amplification, library size selection was performed by cutting out the desired size after 
migration in 8% acrilamid gel electrophoresis. Raw PRO-seq .fastq files were processed and 
aligned to GRCh37 using the proseq2.0.bsh script from the Danko lab43. Processed .bam files 
were sorted and indexed using samtools followed by strand specific bigwig file generation using 
deepTools44. Raw PRO-seq data were deposited in the ArrayExpress database (Accession ID: 
E-MTAB-9019). 
 
Publicly available datasets 
Data from the following publically available datasets were processed: GSE74912 (ATAC-seq 
for hematopoietic stem, progenitor and differentiated cells), GSE108266 (AML patient DNase-
seq), GSE29222 (ChIP-seq for RUNX1-ETO), GSE69239 (RNA-seq for thymic progenitor 
cells), GSE93995 and GSE122958 (Hi-C in HL-60 and Jurkat), GSE117107 (Chi-C after 
RUNX1-ETO depletion in Kasumi-1). ATAC-seq, DNase-seq and RNA-seq data were 
analysed as described above, with ATAC-seq and DNase-seq following the same URE 
normalization. Raw ChIP-seq reads were controlled and adapter trimmed using Trim Galore! 
Software (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) and mapped 
against GRCh37 using bowtie2. Multimappers and reads with bad mapping quality were 
removed using samtools and peak calling was performed by MACS2. HiC and CHiC data were 
trimmed using trim option of homerTools followed by alignment to hg19 by bowtie2 and tag 
directory creation by HOMER. Data were visualized using HOMER´s analyzeHiC and 
TreeView3 software.  
 
Statistical analysis 
All data are presented as mean ± standard error mean (SEM). The sample size was determined 
holding the probability of a type-I error at α = 0.05. Statistical analyses were performed using 
GraphPad Prism version 6.0.0 for Windows, GraphPad Software, San Diego, California US 
(www.graphpad.com) and R, R Foundation for Statistical Computing, Vienna, Austria 
(www.R-project.org). Student’s t-test and Mann-Whitney U test were used to compare 
differences between two groups. Kaplan-Meier/log rank for survival probabilities of xenografts. 
P-value of <0.05 was considered statistically significant. 
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Chromosomal conformation capture (3C) 
For 3C, 50 million cells were prepared for chromatin cross-linking (HL60, Jurkat, Kasumi-1) 
and centrifuged for 10 min at 200g. Briefly, cell pellets were then resuspended in 21.7 ml fresh 
culture medium used for cell growth. 1445µL (microliter) of 16% formaldehyde (vol/vol) was 
added to cross-link cells, gently mixed by pipetting and incubated at room temperature for 10 
min. 1.25ml (milliliter) of 2.5M (molar) glycin was added, incubated for 5 min at room 
temperature and followed by 15 min on ice to stop cross-linking completely. Cross-linked cells 
were centrifuged for 10 min at 400g, supernatant was removed and cells were quick-frozen on 
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